Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24175882 | 0.84 | ESR1 (0.39) | ESR1ESR2CYP3A4CHRM1ALOX15 | |
| SCHEMBL26501439 | 0.82 | TRPA1 (0.33) | ESR1ESR2CYP3A4CHRM1ADRA1A | |
| SCHEMBL27062915 | 0.73 | ESR1 (0.41) | ESR1ESR2CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL24175936 | 0.73 | GABRA1 (0.45) | MAOAMEN1HSP90AA1KMT2AATM | |
| SCHEMBL12671647 | 0.73 | CYP3A4 (0.48) | ESR1ESR2CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL26666986 | 0.70 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL26731838 | 0.69 | ESR1 (0.36) | ESR1ESR2CYP3A4CHRM1ALOX15 | |
| SCHEMBL10306619 | 0.68 | MEN1 (0.50) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL23112220 | 0.68 | CYP1A2 (0.34) | ESR1ESR2CYP3A4TDP1TSHR | |
| SCHEMBL24175927 | 0.68 | ESR1 (0.39) | ESR1ESR2CYP3A4CHRM1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040080-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | ESR1 664/4885ESR2 1465/4885CYP3A4 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.